2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2584

Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Abstract Number: 2585

Serum 14-3-3η Is an RA Specific Mechanistic Marker
Abstract Number: 2586

Cardiac Magnetic Resonance Imaging Reveals Myocardial Damage in Patients with Active Rheumatoid Arthritis
Abstract Number: 2587

CRP and 14-3-3η Are Each Associated with Joint Damage Progression, Their Titres Do Not Correlate and Are Better Predictors of Progression Together Than Alone
Abstract Number: 2588

Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women
Abstract Number: 2589

Associations Between 49 Susceptibility SNPs and Disease Activity Including Radiographic Damage in Early Untreated Rheumatoid Arthritis
Abstract Number: 2590

Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis
Abstract Number: 2591

Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Abstract Number: 2592

Rheumatoid Arthritis Patients with Many Autoantibodies Have Different Characteristics at Presentation Compared to Patients with Few Autoantibodies
Abstract Number: 2593

Relationship Between Index of Activity Speed (Time Up and Go test) and Patient-Reported Outcome in Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Abstract Number: 2594

Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Abstract Number: 2595

Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year
Abstract Number: 2596

Less Musculoskeletal Ultrasound Power Doppler Activity Seen in Obese Rheumatoid Arthritis
Abstract Number: 2597

Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease
Abstract Number: 2598

Neutrophil Extracellular Trap Levels Measured By Cell Free Nucleosome ELISA in Serum Are Highly Specific and Sensitive for Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].